Breaking News

Accelovance Acquires Radiant Development

March 7, 2013

Expands range of therapeutic expertise

Accelovance, Inc. has acquired Radiant Development, the CRO division of Radiant Research, expanding its range of therapeutic areas. Accelovance has extensive experience with vaccine, infectious disease, and oncology markets, while Radiant has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device. Financial terms were not disclosed.  
Radiant Development has operations in Stuart, FL, Chicago, IL, and Durham, NC, and has established strategic partnerships in Europe and Asia to offer global study capabilities. Radiant Development will operate as a division of Accelovance, providing full service clinical capabilities, including project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.
"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company. Core values focused on meeting our client needs, open communication and relationships built on honesty and trust are important similarities between our organizations," said Stephen J. Trevisan, Accelovance president and chief executive officer.
"With a shared vision of an innovative approach to execution, exceptional customer service, and focus on providing value to our clients, Radiant Development is delighted to join forces with Accelovance to offer expanded leading edge service solutions to our clients," said Vita Lanoce, senior vice president of development.

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research